The long-term blockade of IL-1 has been found to restore the clinical equilibrium in many systemic inflammasomopathies of childhood, and IL-1 inhibitors have become cardinal weapons in managing both monogenic innate immunity defects and a plethora of polygenic diseases occurring in children, including different skin disorders [56]. This evidence concerns the gene IL1A and skin disorder.